Special Issue

Antibiotic Resistance and Coping Strategies of Methicillin-Resistant *Staphylococcus* Species

Message from the Guest Editor

Staphylococcus aureus and other *Staphylococcus* species are significant etiological factors of infection developing multiple mechanisms of antibiotic resistance, which are transferred rapidly between the strains in both hospital and community settings. The problem is particularly evident in the case of methicillin-resistant *S. aureus* (MRSA), which previously spread primarily in a hospital setting as hospital-acquired MRSA (HA-MRSA) but is nowadays increasingly found in community settings as community-acquired MRSA (CA-MRSA), displaying high infectivity and virulence. Prevention of methicillin-resistant *Staphylococcus* species transmitted in health care facilities is a major infection control challenge. Previous antibiotic treatments used are ineffective, so exploring alternative therapies is important. In this Special Issue, we encourage research to clarify resistance mechanisms of *Staphylococcus aureus*. Papers about alternative therapies to solve the resistance of *Staphylococcus aureus* such as phages, new antimicrobial drugs and antimicrobial combinations will be welcomed.

Guest Editor

Prof. Dr. Katarzyna Garbacz
Department of Oral Microbiology, Medical Faculty, Medical University of Gdansk, 80-204 Gdansk, Poland

Deadline for manuscript submissions

closed (31 May 2025)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 10.2
Indexed in PubMed

mdpi.com/si/181499

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 10.2
Indexed in PubMed

mdpi.com/journal/antibiotics

MDPI

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)